Document:

SECOND AMENDMENT TO CONSULTING AGREEMENT
DATED FEBRUARY 15, 2011

BY AND BETWEEN

EMMES GROUP CONSULTING LLC

AND

GENESIS BIOPHARMA, INC.

 

THIS SECOND AMENDMENT
TO THE CONSULTING AGREEMENT (“Amendment”) dated February 12, 2012 (“Effective Date”) is made and entered
into by and between Emmes Group Consulting LLC, having its principle place of business at 92 Natoma Street, Suite 200, San Francisco,
CA 94105, (hereinafter referred to as “EMMES”), and Genesis Biopharma, Inc., a Nevada Corporation, a having a principal
place of business at 10880 Wilshire Blvd., Suite 950, Los Angeles, CA 90024 (hereinafter referred to as “GENESIS”).

 

All capitalized terms
used in this Amendment shall have the same meanings given such terms in the CONSULTING AGREEMENT (as hereinafter defined) unless
expressly superseded by the terms of this Amendment.

 

RECITALS

 

WHEREAS, on February
15, 2011, EMMES and GENESIS entered into that certain Consulting Agreement (the “Agreement”), pursuant to the terms
of which EMMES agreed to provide certain consulting services to GENESIS;

 

WHEREAS, the Agreement
sets forth certain amounts of compensation to paid by GENESIS to EMMES; and,

 

WHEREAS, EMMES and
GENESIS now desire to enter into this Amendment for the purposes of amending the Agreement, as hereinafter set forth.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

Section 1(b) shall now read:

 

(b) Term of Engagement. Unless terminated
earlier as provided herein, the term of the Engagement shall commence effective as of February 15, 2011 and shall continue until
December 31, 2015 (the “Termination Date”). If Consultant continues to perform consulting services for the Company
after the Termination Date, then, unless otherwise agreed in writing, (i) the Engagement shall continue for an unspecified term
at the compensation rate set forth in Section 3(a)(i) herein, and (ii) either party may terminate the Engagement immediately with
our without cause by giving the other party written notice of termination.

 

Section 3(a)(i) shall now read:

 

		(i)	Sixty Thousand Dollars ($60,000) per month commencing February 15, 2012 and ending on the Termination
Date; and,

 

    	1

    	 

    

 

Section 3(b) shall now read:

 

(b) Payment Schedule. The Company
shall make payment to Consultant by bank wire transfer in the lawful currency of the United States of America on the tenth (10th)
day of each month during the term of the Engagement.

 

Sections 3(b)(i) and 3(b)(ii) are deleted
in their entirety.

 

IN WITNESS WHEREOF,
both EMMES and GENESIS have executed this First Amendment to the Consulting Agreement by their duly authorized representatives.

 

	FOR EMMES GROUP CONSULTING LLC:	 	FOR GENESIS BIOPHARMA, INC.:
	 	 	 
	 	 	 
	Martin F. Schroeder	 	Anthony J. Cataldo
	 	 	 
	 	 	 
	EVP & Managing Director	 	Chairman & Chief Executive Officer
	Title	 	Title
	 	 	 
	 	 	 
	Date	 	Date

 

    	2AMENDMENT TO CONSULTING AGREEMENT DATED
FEBRUARY 15, 2011

BY AND BETWEEN

EMMES GROUP CONSULTING LLC

AND

GENESIS BIOPHARMA, INC.

 

THIS FIRST AMENDMENT
TO THE EXCLUSIVE LICENSE AGREEMENT (“Amendment”) dated August 1, 2011 (“Effective Date”) is made and entered
into by and between Emmes Group Consulting LLC, having its principle place of business at 92 Natoma Street, Suite 200, San Francisco,
CA 94105, (hereinafter referred to as “EMMES”), and Genesis Biopharma, Inc., a Nevada Corporation, a having a principal
place of business at 10880 Wilshire Blvd., Suite 950, Los Angeles, CA 90024 (hereinafter referred to as “GENESIS”).

 

All capitalized terms
used in this Amendment shall have the same meanings given such terms in the Exclusive License Agreement (as hereinafter defined)
unless expressly superseded by the terms of this Amendment.

 

RECITALS

 

WHEREAS, on February
15, 2011, EMMES and GENESIS entered into that certain Consulting Agreement (the “Agreement”), pursuant to the terms
of which EMMES agreed to provide certain consulting services to GENESIS;

 

WHEREAS, the Agreement
sets forth certain amounts of compensation to paid by GENESIS to EMMES; and,

 

WHEREAS, EMMES and
GENESIS now desire to enter into this Amendment for the purposes of amending the Agreement, as hereinafter set forth.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

Section 1(b) shall now read:

 

(b) Term of Engagement. Unless terminated
earlier as provided herein, the term of the Engagement shall commence effective as of February 15, 2011 and shall continue until
December 31, 2011 (the “Termination Date”). If Consultant continues to perform consulting services for the Company
after the Termination Date, then, unless otherwise agreed in writing, (i) the Engagement shall continue for an unspecified term
at the compensation rate set forth in Section 3(a)(i) herein, and (ii) either party may terminate the Engagement immediately with
our without cause by giving the other party written notice of termination.

 

Section 3(a)(i) shall now read:

 

(i)   Twenty Thousand Dollars
($20,000) per month commencing July 11, 2011 and ending on the Termination Date; and,

 

Section 3(b) shall now read:

 

(b)   Payment Schedule.
The Company shall make payment to Consultant by bank wire transfer in the lawful currency of the United States of America on the
tenth (10th) day of each month during the term of the Engagement.

 

Sections 3(b)(i) and 3(b)(ii) are deleted
in their entirety.

 

    	1

    	 

    

 

SIGNATURE PAGE

 

IN WITNESS WHEREOF,
both EMMES and GENESIS have executed this First Amendment to the Consulting Agreement by their duly authorized representatives.

 

	FOR EMMES GROUP CONSULTING LLC:	 	FOR GENESIS BIOPHARMA, INC.:
	 	 	 
	 	 	 
	Martin F. Schroeder	 	Anthony J. Cataldo
	 	 	 
	 	 	 
	EVP & Managing Director	 	Chairman & Chief Executive Officer
	Title	 	Title
	 	 	 
	 	 	 
	Date	 	Date

 

    	2CONSULTING AGREEMENT

 

This Consulting Agreement(the “Agreement”)
is made as of this ___day of _________ 2011 by and between Theorem Capital, LLC, a California limited liability company with offices
at 10880 Wilshire Blvd., Suite 950, Los Angeles, CA 90024 (the “Consultant”) and Genesis Biopharma, Inc., a Nevada
corporation with offices at 11500 Olympic Blvd, Suite 400 Los Angeles, Ca 90064 (the “Company”).

 

WHEREAS, Consultant has substantial expertise
that be useful to the Company, which the Company desires to obtain; and

 

WHEREAS, the Company desires Consultant
to provide certain consulting services to the Company and Consultant is agreeable to performing such services for the Company.

 

NOW, THEREFORE, inconsideration of the mutual
covenants hereinafter stated, the parties hereto agree as follows:

 

1.          APPOINTMENT.

 

The Company hereby engages Consultant and
Consultant agrees to render services to the Company as a consultant upon the terms and conditions hereinafter set forth.

 

2.          TERM.

 

The term of this Agreement shall commence
on the date of this Agreement as set forth above and shall terminate on the sixth (6th) month anniversary of the date
of this Agreement, unless terminated or extended in accordance with a valid provision contained herein or by a subsequent agreement
between the parties.

 

3.           SERVICES.

 

During the term of this Agreement, Consultant
shall assist the Company in general corporate activities including but not limited to strategic and financial planning; management
and business operations; financial projections and investor presentation materials; and any other consulting or advisory services
which the Company reasonably requests that Consultant provide to the Company.

 

4.           DUTIES OF THE COMPANY.

 

The Company shall provide Consultant, on
a regular and timely basis, with all approved data and information about it, its subsidiaries, its management, its products and
services and its operations shall be reasonably requested by Consultant, and shall advise Consultant of any facts which would affect
the accuracy of any data and information previously supplied pursuant to this paragraph. The Company shall promptly supply Consultant
with full and complete copies of all financial reports, all filings with all federal and state securities agencies; with all data
and information supplied by any financial analyst, and with all brochures or other sales materials relating to its products or
services. Notwithstanding the foregoing, the Company shall not provide Consultant with any information which is considered to be
material non-public information.

 

5.          COMPENSATION.

 

Upon the execution of this Agreement, Company
agrees to pay Consultant the following as consideration for the services rendered under this Agreement:

 

    	 

    	 

    

 

(a)         The Company shall immediately,
but in no event later than three (3) business days following the date of this Agreement, issue to Consultant a warrant to purchase
1,500,000 shares of common stock of the Company (the “Warrant”). The Warrant will be available for exercise for a period
of five years and have an exercise price of $1.50 per share.

  

(b)        The underlying common-stock of the Warrant
shall be included the Company’s existing shelf registration.

 

6.           BENEFICIAL OWNERSHIP OF SHARES.

 

Consultant’s beneficial ownership
of common stock of the Company shall not exceed 4.99% of the outstanding Shares the Company’s common stock. For purposes
of this paragraph, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of
1934, as amended, and Regulations 13D-G thereunder. Consultant may waive the limitations set forth herein to increase its beneficial
ownership to 9.9% with sixty-one (61) days written notice to the Company.

 

7.           COSTS AND EXPENSES.

 

Subject to the prior approval of the Company,
which approval shall not be reasonably withheld, Consultant in providing the foregoing services shall not be responsible for any
out-of-pocket costs, including, without limitation, travel, lodging, telephone, postage and Federal Express charges. Consultant
shall provide the Company with detailed accounting of monthly expenses related to the Agreement. Payment for these expenses shall
be made to Consultant within 15 days after submission to the Company.

 

8.           INDEMNIFICATION.

 

(a)        The Company agrees to indemnify, defend,
and shall not hold harmless Consultant and/or his agents, and to defend any action brought against said parties with respect to
any claim, demand cause of action, debt or liability, including reasonable attorneys’ fees to the extent that such action
us based upon a claim that: (i) is true, (ii) would constitute a breach of any of the Company’s representations, warranties,
or agreements hereunder, or (iii) arises out of the negligence or willful misconduct of the Company, or any of the Company’s
content to be provided by the Company and does not violate any rights of third parties, including, without limitation, rights of
publicity, privacy, patents, copyrights, trademarks, trade secrets, and/or licenses.

 

(b)        Consultant agrees to indemnify, defend
and shall hold harmless the Company, its directors, employees and agents, and defend any action brought against same with respect
to any claim, demand, cause of action, or liability, including reasonable attorneys’ fee, to the extent that such an action
arises out of the gross negligence or willful misconduct of Consultant.

 

(c)        Notice. In claiming indemnification
hereunder, the indemnified party shall promptly provide the indemnifying party with written notice of any claim, which the indemnified
party believes falls within the scope of the foregoing paragraphs. The indemnified party may, at its expense, assist in the defense
if it so chooses, provided that the indemnifying party shall control such defense, and all negotiations relative to the settlement
of any such claim. Any settlement intended to bind the indemnified party shall not be final without the indemnified party’s
written consent, which shall not be unreasonably withheld.

 

9.           INDEPENDENT CONTRACTOR STATUS.

 

It is understood and agreed that Consultant
will for all purposes hereof be deemed to be an independent contractor and will not, unless otherwise expressly authorized by the
Company, have any authority to act for or represent the Company in any way, execute any transaction on behalf of the Company or
otherwise de deemed an agent of the Company. No federal, state or local withholding deductions will be withheld from any amounts
owed by the Company to Consultant hereunder unless otherwise required by law.

 

    	 

    	 

    

 

10.           CONFIDENTIALITY.

 

The Company agrees that it will not disclose,
and will not include in any public announcement, the name of the Consultant, unless expressly agreed to by the Consultant or unless
and until such disclosure is required by law or applicable regulation, and the only to the extent of such requirement.

 

11.           MISCELLANEOUS.

 

(a)        Termination. Subsequent to and no less
than 30 days after the execution of this Agreement, this Agreement may be terminated by either Party upon written notice to the
other Party for any reason. The termination shall be effective within five (5) business days from the date of such notice. Termination
of this Agreement shall cause Consultant to cease providing services under this Agreement; however, termination for any reason
whatsoever shall not decrease or eliminate the compensatory obligations of the Company as outlined in Section 5 of this Agreement.

 

(b)        Modification. This Agreement sets forth
the entire understanding of the Parties with respect to the subject matter hereof. This Agreement may be amended only in writing
signed by both Parties.

 

(c)        Notices. Any notice required or permitted
to be given hereunder shall be in writing and shall be mailed or otherwise delivered in person or by facsimile transmission at
the address of such party set forth above or to such other address or facsimile telephone number as the party shall have furnished
in writing to the other party.

 

(d)        Notice. In claiming indemnification
hereunder, the indemnified party shall promptly provide the indemnifying party with written notice of any claim, which the indemnified
party believes falls within the scope of the foregoing paragraphs. The indemnified party may, at its expense, assist in the defense
if it so chooses, provided that the indemnifying party shall control such defense, and all negotiations relative to the settlement
of any such claim. Any settlement intended to bind the indemnified party shall not be final without the indemnified party’s
written consent, which shall not be unreasonably withheld.

 

(e)        Assignment. The Shares granted under
this Agreement are assignable at the sole discretion of the Consultant.

 

(f)        Severability. If any provision of this
Agreement is invalid, illegal, or unenforceable, the balance of this Agreement shall remain in effect, and if any provision is
inapplicable to any person or circumstance, it shall nevertheless remain applicable to all other persons and circumstances.

 

(g)        Disagreements. Any dispute or other
disagreement arising from or out of this Agreement shall be submitted to arbitration under the rules of the American Arbitration
Association and the decision of the arbiter(s) shall be enforceable in any court having jurisdiction thereof. Arbitration shall
occur only in Los Angeles, California. The interpretation and the enforcement of this Agreement shall be governed by the laws of
this State of California as applied to residents of the State of California relating to contracts executed in and to be performed
solely within the State of California. In the event any dispute is arbitrated, the prevailing party (as determined by the arbiter(s))
shall be entitled to recover that party’s reasonable attorney’s fees incurred (as determined by the arbiter(s)).

 

Each party may sign identical counterparts
of this Agreement with the same effect as if both parties signed the same document. A copy of this Agreement signed by one party
and delivered by facsimile or electronic transmission to the other party shall have the same effect as the delivery of an original
of this Agreement containing the original signature of such party.

 

    	 

    	 

    

 

IN WITNESS WHEREOF, this Agreement has been
executed by the Parties as of the date first above written.

 

	GENESIS BIOPHARMA, INC.	 	BRISTOL CAPITAL, LLC
	 	 	 
	 	 	 
	Name	 	Name: Paul Kessler
	Title	 	Title:  Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]